Alpha Cognition Inc. (NASDAQ: ACOG), a biopharmaceutical company focused on developing treatments for neurodegenerative diseases, announced its financial results for the fiscal year ended December 31, 2025. The company reported total revenue of $10.2 million, which includes $6.8 million from net product sales of its Alzheimer’s treatment, ZUNVEYL, and $3.4 million from licensing revenue. The fourth quarter alone saw a significant increase in demand, with net product revenue reaching $2.5 million and a 62% increase in bottles dispensed compared to the previous quarter. December marked the strongest month since the product's launch, with 4,941 bottles dispensed. The company also executed a second national pharmacy benefit manager (PBM) contract, enhancing its market position in long-term care settings. Alpha Cognition ended the year with a robust cash position of $66 million, supporting its goal of achieving operational profitability by 2027. The company plans to host a conference call to discuss these results further, indicating a proactive approach to investor relations and transparency.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.